Bio-Rad Reports Q3 2026 Results with Improved Margins Amid Life Science Challenges
Bio-Rad (BIO) reported third-quarter revenue of $656.4 million, a slight increase of 0.7% on a currency-neutral basis. While Clinical Diagnostics saw growth of 2.8%, the Life Science segment faced a 2.4% decline due to lower process chromatography sales and academic market headwinds. Despite these challenges, the company achieved margin expansion, with non-GAAP gross margins rising to 54.5% from 53.5% in the prior year. The company is navigating external pressures including elevated logistics costs expected to persist into 2027 and pricing shifts in China due to updated regulatory guidelines. To drive long-term value, Bio-Rad is implementing a restructuring plan aimed at $30 million to $35 million in annual savings by 2028 and remains focused on M&A opportunities with revenues between $100 million and $500 million.
Topics: clinical diagnostics gross margin life science revenue net income revenue growth
Read the full article at Motley Fool
Part of the story Cogent Communications Reports Q3 2026 Results with Improved EBITDA Margins and Wavelength Growth (22 articles)